CORCEPT THERAPEUTICS INC

Company Overview

Corcept Therapeutics (CORT) is a commercial-stage biotechnology company developing selective glucocorticoid receptor (GR) modulators to treat endocrine, oncologic, metabolic and neurologic disorders. Its marketed product is Korlym (mifepristone) in the U.S., and the company is advancing a late-stage pipeline led by relacorilant (NDA submitted; PDUFA date disclosed) plus oncology and neurology programs (ROSELLA, GRACE/GRADIENT, DAZALS, MONARCH). Corcept operates a hybrid commercial/R&D model with a U.S. specialty sales force, patient-support programs, heavy outsourced clinical/manufacturing operations, substantial R&D spend (~$247M in 2024) and meaningful recent revenue growth (net product revenue $675M in 2024).

Executive Compensation Practices

Given Corcept’s profile, executive pay is likely heavily weighted toward equity and milestone-linked long-term incentives: stock options/RSUs and performance awards tied to regulatory milestones (e.g., relacorilant NDA/PDUFA outcomes), clinical readouts (ROSELLA, GRACE/GRADIENT) and commercial performance (Korlym sales/volume). Annual cash compensation and bonuses for commercial leaders are expected to reflect revenue growth and gross-margin metrics, while R&D leaders may have bonus metrics tied to trial enrollment, NDA submissions and data milestones; retention awards are common given outsourced CRO/CMO dependencies and specialized talent needs. The company’s recent strong revenue, material R&D investment, and active buyback program (tender offer and repurchases) create incentives to align pay with both near-term commercial execution and longer-term regulatory/clinical success, subject to typical healthcare compliance constraints (e.g., incentives cannot improperly influence prescribing).

Insider Trading Considerations

Material clinical milestones (NDA/PDUFA dates, pivotal trial readouts) and commercial developments (authorized generic launch, pricing/reimbursement shifts) are the most likely drivers of material nonpublic information for Corcept and therefore define the periods when insiders will be in blackout for trading. The company’s history of share repurchases and tender offers, combined with stock-based pay, increases the probability of insiders implementing 10b5-1 plans or using open-market buys/sells to manage concentrated equity positions; any coordinated repurchase activity can also affect observed insider transactions. Regulatory and sector-specific risks—FDA decisions, patent litigation (e.g., generic challenges), and reimbursement changes tied to U.S. policy—are events that typically trigger heightened Form 4/Form 144 reporting and secondary-market volatility, so users should monitor filings around clinical calendar dates, earnings, and major litigation or payer announcements.